Compare VALU & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VALU | SENS |
|---|---|---|
| Founded | 1931 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.5M | 301.2M |
| IPO Year | 1995 | 2014 |
| Metric | VALU | SENS |
|---|---|---|
| Price | $32.95 | $6.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.38 |
| AVG Volume (30 Days) | 1.2K | ★ 973.5K |
| Earning Date | 03-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | ★ 8.91 | N/A |
| EPS | ★ 1.92 | N/A |
| Revenue | ★ $36,257,000.00 | $16,389,000.00 |
| Revenue This Year | N/A | $74.15 |
| Revenue Next Year | N/A | $58.60 |
| P/E Ratio | $17.01 | ★ N/A |
| Revenue Growth | 1.08 | ★ 19.85 |
| 52 Week Low | $32.16 | $0.41 |
| 52 Week High | $40.50 | $8.75 |
| Indicator | VALU | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 59.61 |
| Support Level | N/A | $6.62 |
| Resistance Level | $38.30 | $6.87 |
| Average True Range (ATR) | 0.77 | 0.39 |
| MACD | -0.04 | 0.15 |
| Stochastic Oscillator | 8.16 | 75.40 |
Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.